5-MAPDB
5-MAPDB is the N-methyl homolog of 5-APDB, standing in the same relation to it as MDMA does to MDA. It is a serotonin-preferring benzofuran entactogen with almost no human data. It carries the serotonergic neurotoxicity, hyperthermia, and serotonin-syndrome concerns typical of the MDMA class.
01 Overview
5-MAPDB appeared as an obscure research chemical entactogen. By analogy to 5-APDB, it is expected to produce MDMA-like emotional effects with a serotonergic, moderately stimulating character. Very little anecdotal or laboratory data exists.
There is no formal human pharmacology or toxicology. As a serotonin releaser it carries the theoretical neurotoxicity and serotonin-syndrome risks of the class, and benzofurans specifically raise 5-HT2B cardiovascular concerns. Likely covered by analog/psychoactive-substances laws.
02 Mechanism
N-methylated benzofuran serotonin-preferring releaser at monoamine transporters, predicted to give MDMA-like entactogenic effects.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 50–90 mg | Oral | Estimated; potency poorly defined |
| Common | 90–150 mg | Oral | Estimated common range, high uncertainty |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Entactogenic effectsExpected MDMA-like emotional openness by analogy; direct reports are scarce. | Presumed moderate | Unconfirmed | |
| Mild stimulationPredicted moderate stimulation with serotonergic bias. | Mild | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeTheoretical serious risk from serotonin release, especially in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Cardiovascular strainBenzofurans carry 5-HT2B agonism and cardiovascular load concerns. | Moderate | Common (predicted) | Unconfirmed | |
| Serotonergic neurotoxicityTheoretical axonal neurotoxicity as with the MDMA class. | Severe | Theoretical | Preclinical |